In the Q4 fiscal year 2017, Dr Reddy’s profit has increased by 2.8 times to Rs 337.6 crore while it was Rs 122.6 crores in FY16. However, Dr Reddy’s revenue has dropped by 4.8 percent in Q4FY17 while it was Rs 3795 crore during the corresponding quarter in FY16.
Dr Reddy’s had reported that its EBITDA has increased from Rs 480 crore to Rs 630 crore in Jan-Mar quarter on YoY basis. Its EBITDA margin has increased from 12.8% to 17.7% on YoY basis in jan-mar quarter.
On YoY basis in Q4, Dr. Reddy’s global generic sales dropped by 5 percent from Rs 3077.4 crore to Rs 2,913.8 crore. In the same quarter its generic sales in North America dropped 19 percent from Rs 1895 crore to Rs 1534.9 crore.
In the fourth quarter on YoY basis, Dr Reddy’s sales of generic drugs in Latin Europe have increased by 17 percent from Rs 206.6 crore to Rs 175.9 crore. While in the same quarter on YoY basis, sales in India rose 8 percent from Rs 526.7 crore to Rs 571.1 crore.